Compare Ascendis Pharma A/S (ASND) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Fiverr International Ltd — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Fiverr International Ltd trades at $10.97 (market cap $396.90M). The key difference: Ascendis Pharma A/S is far larger — about 44.7× Fiverr International Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | FVRR | |
|---|---|---|
Market Cap | $17.74B | $396.90M |
Sector | Health | Industrials |
52-Week High | $277.18 | $27.25 |
52-Week Low | $163.32 | $9.62 |
Enterprise Value | $18.11B | $127.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Fiverr International (FVRR) trades at $11.04, up 1.1% on the day, with a bullish technical signal and strong valuation metrics including a P/E of 14.34 and P/S of 0.95. Revenue grew to $430.91M in 2025, with net income reaching $20.98M, though Q1 2026 EPS missed expectations. The company maintains a robust gross margin of 81.86% and has beaten earnings estimates in two of the last three quarters, with Q2 2026 results due July 29, 2026.
The outlook is mixed: low valuations and improving profitability support upside, but declining active buyers and a pending legal investigation pose risks. Analyst consensus is cautious with 41% buy ratings. Near-term performance hinges on Q2 earnings demonstrating growth stabilization amid competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
